NeuroSense (NRSN) Therapeutics announced that the company received formal written notice from The Nasdaq Stock Market that the company has regained compliance with Nasdaq’s stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1). The company’s Ordinary Shares will continue to be listed and trade on The Nasdaq Capital Market under the symbol “NRSN”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense files to sell 5.28M ordinary shares for holders
- NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC
- NeuroSense enters binding term sheet to advance PrimeC for ALS
- NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position
- NeuroSense reports first nine months EPS (48c) vs. (55c) last year